MedPath

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

Phase 3
Completed
Conditions
Uveitis, Anterior
Panuveitis
Interventions
Drug: Placebo
Registration Number
NCT00404885
Lead Sponsor
Lux Biosciences, Inc.
Brief Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
108
Inclusion Criteria
  • Documented history of non-infectious anterior, anterior and intermediate- or panuveitis
  • Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.
  • Grade of 2+ or higher for anterior chamber cells at time of enrollment
  • Considered by the investigator to require corticosteroid-sparing therapy.
  • Subjects not planning to undergo elective ocular surgery during the study
Exclusion Criteria
  • Uveitis of infectious etiology
  • Presence of an ocular toxoplasmosis scar
  • An immune suppression regimen that includes an alkylating agent within the previous 90 days

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
LX211, 0.2 mg/kgLX211-
LX211, 0.4 mg/kgLX211-
LX211, 0.6 mg/kgLX211-
Primary Outcome Measures
NameTimeMethod
anterior chamber cells16 and 24 weeks
Secondary Outcome Measures
NameTimeMethod
BCVA24 weeks
macular thickness16 and 24 weeks

Trial Locations

Locations (30)

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Retinal Consultants of Arizona

🇺🇸

Phoenix, Arizona, United States

University of Illinois - Chicago

🇺🇸

Chicago, Illinois, United States

Wilmer Eye Institute

🇺🇸

Baltimore, Maryland, United States

Massachusetts Eye and Ear Infirmary

🇺🇸

Boston, Massachusetts, United States

Massachusetts Eye Research and Surgery Institute

🇺🇸

Cambridge, Massachusetts, United States

Associated Retinal Consultants, PC

🇺🇸

Grand Rapids, Michigan, United States

Tauber Eye Center

🇺🇸

Kansas City, Missouri, United States

New York Eye & Ear Hospital

🇺🇸

New York, New York, United States

Duke University Eye Center, Erwin Road

🇺🇸

Durham, North Carolina, United States

Scroll for more (20 remaining)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.